ThromboGenics sets Jetrea U.S. launch as Jan. 14

Leuven, Belgium-ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, confirms its Jetrea U.S. launch date of January 14.

Jetrea (ocriplasmin) intravitreal injection is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion (VMA). The U.S. price for a single-use glass vial of Jetrea is set at $3,950.

Jetrea represents a paradigm shift and for the first time offers a pharmacological treatment option to patients suffering with symptomatic VMA. The FDA approved Jetrea in October as the first pharmacological agent for the treatment of symptomatic VMA. The recommended dose of Jetrea is 0.125 mg (0.1 mL) of the diluted solution administered by intravitreal injection to the affected eye as a single injection.

Approval was based on the data from ThromboGenics’ Phase III program where Jetrea was shown to be superior to placebo for the treatment of symptomatic VMA (26.5% vs. 10.1%; p < 0.01). Treatment with Jetrea was associated with some, mainly transient, ocular adverse events.

For more information, go to www.jetrea.com.